Karl-Heinz Weiss

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Medicine, Oncology, Pharmacology +11

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer

Ramona Rudalska, Daniel Dauch, Thomas Longerich et al. · Nature Medicine · 2014 · 277 citations · Full text

Medicine, Molecular Biology, Oncology +16

Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis

Christian Rupp, Alexander Rössler, Emina Halibasic et al. · Alimentary Pharmacology & Therapeutics · 2014 · 108 citations · Full text

Medicine, Pathology, Early Detection +11

Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis

Sebastian Torben Jendrek, Daniel Gotthardt, Thomas Nitzsche et al. · Gut · 2016 · 84 citations · Full text

Medicine, Immunology, Pathology +14